Monday July 19, 8:25 am Eastern Time
Company Press Release
New Technologies & Concepts, Inc. Receives
Patient Documentation From Govt. Of Spain
Following Announcement Of Major Breakthrough
In Field Of HIV Research
LAS VEGAS--(BW HealthWire)--July 19, 1999--New Technologies & Concepts, Inc. (NTC), a Research and
Development Company, announced today that as a follow-up to its announcement on June 16, 1999 of its
major breakthrough in the fight against the human immunodeficiency virus (HIV), it has received
documentation from the Government of Spain verifying the authenticity of the patients who have been
treated and sent letters regarding their treatment. Their regular monthly checkups have shown no
recurrence of the virus to date. In fact, ONE HUNDRED PERCENT (100%) of the patients tested showed
COMPLETE REVERSAL of the HIV virus with VIRTUALLY NO SIDE EFFECTS!
The founder of the company, Alfred Flores, an honor graduate of the University of Madrid and the
University of Colorado, has done extensive research into the area of immunology at his own laboratory
located just outside of Lisbon, in Portugal. It was there that he developed the Plasma Plus formula, which
was used to treat these patients. The letters received further verify that the tests conducted on patients
in Madrid, which showed complete reversal from the immune system of the HIV infection, still show no
reintroduction of the virus after a period of more than eighteen months.
The letters give the patient's name and address, their patient number, identification number, their
original CD-4 counts at the commencement of the treatment, and their current CD-4 counts after more
than 18 months.
The patients were originally diagnosed with AIDS in 1995 at the Hospital of Madrid and Mr. Flores was then
given permission by the courts to treat them with Plasma Plus which is done, in most cases, over a
3-month period.
This documentation verifies that all of the patients have been tested monthly at the General Hospital in
Madrid over the past 18 months. Their blood profiles show that prior to being administered the Plasma
Plus treatment, some of the patients had CD-4 counts under 400, usually associated with AIDS, and some
even as low as 200.
They are all currently in the normal 800 - 1,200 CD-4 count range and aside from taking vitamins and
following a low calorie diet, they have not taken any medication of any kind for the virus since the
original Plasma Plus treatments.
Results from the findings of the Plasma Plus treatment are nothing short of ''Phenomenal,'' according to
the doctors in Madrid who oversaw the treatments.
The majority stockholder in NTC is Uniprime Capital Acceptance, Inc. (OTC BB: UPCA - news) of Las
Vegas, Nevada, a diversified holding company involved in the acquisition of retail automotive dealerships
throughout the United States, along with planned expansion into the areas of non-prime financing,
industry consulting and insurance-related services.
NTC and Uniprime are currently working on additional sites around the world to demonstrate the results of
Plasma Plus before embarking on a worldwide marketing campaign.
The documentation regarding five (5) of the patients will be posted on the Uniprime web-site which is
located at: www.uniprimeinc.com .
In addition to the testimonials of the patients, three (3) of the doctors who participated in the study will
be forwarding their own WRITTEN TESTIMONIALS as to the results of the tests and this information is
expected to be in the hands of Mr. Flores and top Uniprime personnel by next week.
For further information, please contact Mr. Alfred Flores through the corporate offices of Uniprime at
1-888-892-2002 Or 1-702-798-5420.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements
contained herein which are not historical are forward-looking statements that are subject to risks and
uncertainties that could cause actual results to differ materially from those expressed in the
forward-looking statements, including, but not limited to, certain delays beyond the company's control
with respect to market acceptance of new technologies or products or delays in testing and evaluation of
products or in information supplied by others and other risks detailed from time to time in company
documents furnished to investors.
Contact:
Uniprime
Mr. Alfred Flores
888/892-2002
or
702/798-5420 |
